Bladder cancer

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

Retrieved on: 
Friday, January 26, 2024
Patient, PST, Prostate cancer, Carcinoma, Bladder cancer, ASCO, Team Impulse, Society, TSC1, Urethra, GU, TSC2, Progress, Kidney cancer, Cancer

LOS ANGELES, Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA.

Key Points: 
  • LOS ANGELES, Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA.
  • Abstract and poster presentation details are below:
    Date/Time: January 26, 2024 – 11:30 – 1:00 pm; 5:45 – 6:45 pm PST
    In a large real-world database of patients with advanced cancer, 1,828 (4.0%) of the 46,068 patients with GU cancers had at least one inactivating alteration in TSC1 or TSC2
    TSC1 and/or TSC2 inactivating alterations were present in 9.2% of patients with bladder cancer, 6.4% of patients with kidney cancer, and 0.6% of patients with prostate cancer
    Aadi is also presenting an encore Trials-in-Progress (TiP) poster from the ongoing PRECISION 1 study.
  • Session Title: Trials in Progress Poster Session C: Renal Cell Cancer: Adrenal, Penile, Urethral and Testicular Cancers
    Date/Time: January 27, 2024 – 7:00 – 8:00 am; 11:30 am – 1:00 pm PST

Partnership-funded initiative has increased access to smoking cessation support for people with cancer

Retrieved on: 
Wednesday, January 24, 2024
Family, Smoker, Hospital, Smoking, Health, Bladder cancer, Smoking cessation, Survival, Friends, Partnership, Mental health, First Nations, Lung cancer, Risk, Nicotine, Canadian Cancer Society, Acupuncture, Hypnosis, Smoke

For people with cancer, quitting smoking after a cancer diagnosis can make a big difference.

Key Points: 
  • For people with cancer, quitting smoking after a cancer diagnosis can make a big difference.
  • By quitting smoking, a person's cancer treatment becomes more effective and their chance of survival increases by about 40 per cent – making smoking cessation support a critical component of initial cancer treatment and high-quality cancer care.
  • When the Partnership began leading this pan-Canadian initiative to integrate evidence-based smoking cessation into cancer care across Canada, only two provinces were actively helping people with cancer quit smoking.
  • Impact of a Pan-Canadian Initiative, visit Smoking cessation in cancer care across Canada, 2022-23 – Canadian Partnership Against Cancer .

Global Urinary Tract Infection (UTI) Treatment Market is expected to Reach US$ 13,617.4 million by 2034, rising at a 1.9% CAGR- FMI Study

Retrieved on: 
Monday, January 22, 2024
Patient, Catheter, Research, Bladder cancer, UTI, Developed country, Risk, Urinary tract infection, Kidney, System, Cardiac catheterization, Drainage, Infection, FMI, Diagnosis, Prevalence, Medical imaging

NEWARK, Del., Jan. 22, 2024 /PRNewswire/ -- The Urinary Tract Infection (UTI) Treatment Market is estimated to be worth US$   11,244.0 million in 2024 and is projected to be valued at US$ 13,617.4 million in 2034. Between 2024 and 2034, the industry is expected to register a growth rate of 1.9%.

Key Points: 
  • Future Market Insights, Inc. (FMI) predicts a robust expansion of the urinary tract infection (UTI) treatment market, propelled by increasing infection rates, catheter use, and advancements in diagnosis and care.
  • Dive deeper into the intricate dynamics of this burgeoning market and uncover compelling stakeholder opportunities in our comprehensive FMI report.
  • NEWARK, Del., Jan. 22, 2024 /PRNewswire/ -- The Urinary Tract Infection (UTI) Treatment Market is estimated to be worth US$   11,244.0 million in 2024 and is projected to be valued at US$ 13,617.4 million in 2034.
  • Individuals using urinary catheters face an elevated risk of developing complicated urinary tract infections, driving the demand for UTI treatment .

U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations

Retrieved on: 
Friday, January 19, 2024
Potassium, Death, Xerostomia, Patient, State, Overalls, Hyperphosphatemia, Shanda, OS, Bladder cancer, Stomatitis, PD-1, MUC, Survival, Fatigue, Sodium, Calcium, Cohort, Risk, FGFR, PD-L1, Xeroderma, Food, Constipation, Disease, Nail, Creatinine, Johnson & Johnson, Erdafitinib, Neoplasm, FDA, Confidence interval, Diarrhea, New Drug Application, FGFR3, Drug, Appetite, Pharmaceutical industry

RARITAN, N.J., Jan. 19, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for BALVERSA® (erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. BALVERSA® is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. This FDA action converts the April 2019 accelerated approval of BALVERSA® to a full approval based on the clinical and overall survival benefit observed in the Phase 3 THOR study. BALVERSA® is the first oral FGFR kinase inhibitor to be approved, and the first and only targeted treatment for patients with mUC and FGFR alterations.

Key Points: 
  • BALVERSA® is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.
  • This FDA action converts the April 2019 accelerated approval of BALVERSA® to a full approval based on the clinical and overall survival benefit observed in the Phase 3 THOR study.
  • BALVERSA® is the first oral FGFR kinase inhibitor to be approved, and the first and only targeted treatment for patients with mUC and FGFR alterations.
  • This model is part of the Company's ongoing commitment to provide high-quality products, services, access, and support to healthcare professionals and patients.

Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.

Retrieved on: 
Tuesday, January 16, 2024
Oncology, Health, Managed Care, General Health, Clinical Trials, Pharmaceutical, Biotechnology, RWE, Senior, Carcinoma in situ, Patient, Bladder cancer, Ferring Pharmaceuticals, CIS, BCG, Urinary bladder, BCAN, Investment, FDA, NMIBC, Bacillus, Pharmaceutical industry

Approved by the U.S. Food & Drug Administration (FDA) in December 2022, ADSTILADRIN is the first and only FDA-approved intravesical gene therapy for adults with NMIBC who no longer respond to standard therapy.

Key Points: 
  • Approved by the U.S. Food & Drug Administration (FDA) in December 2022, ADSTILADRIN is the first and only FDA-approved intravesical gene therapy for adults with NMIBC who no longer respond to standard therapy.
  • “With our significant manufacturing investments, we have achieved full product supply ahead of schedule.
  • Now that full product supply is available ahead of schedule, Ferring can end the temporary ADSTILADRIN Early Experience Program and dramatically increase patient access.
  • This ongoing study is exploring early utilization, experiences, and outcomes of ADSTILADRIN in the routine care setting.

American Urological Association Announces 2024 Innovation Nexus Showcase Selections

Retrieved on: 
Wednesday, January 10, 2024
Nexus, Woman, Patient, Fertility, American Urological Association, Trauma, Therapy, Prostate cancer, Artificial intelligence, Bladder cancer, Urology, Showcase, Cystoscopy, Funding of science, FACS, University, Surgery, Incontinence, Carboxypeptidase, Hyperoxaluria, Conference, Urinary tract infection, Information technology, Urethra, Patient safety, AUA, Medical imaging

Baltimore, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce the ten companies chosen through a rigorous and highly competitive selection process for the second annual Innovation Nexus Showcase.

Key Points: 
  • Baltimore, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce the ten companies chosen through a rigorous and highly competitive selection process for the second annual Innovation Nexus Showcase.
  • Innovation Nexus is a long-term commitment by the AUA to sustain a urology incubator to advance discoveries with key stakeholders to benefit urologic patient care.
  • As part of the multi-faceted program, the AUA will host an annual Innovation Nexus Conference, with the second event being held on May 2 in San Antonio, TX, before the AUA Annual Meeting.
  • For more information on the Showcase and to register to attend the May 2 event, please visit: https://auanexus.org/

Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board

Retrieved on: 
Wednesday, January 10, 2024
Stanford University, Leukemia, Monroe Dunaway Anderson, Research, Metastasis, Ipilimumab, Cancer, Autoimmune disease, CODEX, GBM, University, National academy, Bladder cancer, MD Anderson Cancer Center, RNA, Teal, CD28, Defense, EZH2, Nobel Prize, Invention, Translational research, Health, Cell biology, Pathology, Woman, Immunotherapy, SAB, Emil Frei, Patient, Associate, MD, Roche, Burroughs Wellcome Fund, Society, FDA, ATAC, ASCI, Doctor of Philosophy, Clinical trial, Immune system, Pharmaceutical industry

Professor Nolan will transition from his role on the Akoya Board of Directors to Chair of the SAB.

Key Points: 
  • Professor Nolan will transition from his role on the Akoya Board of Directors to Chair of the SAB.
  • He co-founded Akoya Biosciences in 2015 and is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine.
  • Dr. Allison has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy.
  • This finding and a great deal of persistence paved the way for the field of immune checkpoint blockade therapy for cancer.

Global Stoma/Ostomy Care Market Analysis Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 11, 2024
Health, Surgery, Medical Supplies, Other Health, Patient, Growth, Bladder cancer, Stoma (medicine), COVID-19, Prevalence, Colorectal cancer, Pet industry

The "Stoma/Ostomy Care - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stoma/Ostomy Care - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Stoma/Ostomy Care Products estimated at US$3.3 Billion in the year 2022, is projected to reach a revised size of US$5.1 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2022-2030.
  • Ostomy Care Bags, one of the segments analyzed in the report, is projected to record 5.4% CAGR and reach US$4.4 Billion by the end of the analysis period.
  • The report provides insights into the competitive landscape, categorizing global key competitors' market share in 2022 and their competitive market presence as strong, active, niche, or trivial.

Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion

Retrieved on: 
Tuesday, January 9, 2024
Action plan, E pluribus unum, Woman, Bladder cancer, Marketing, Health, Elimination, Society, Cancer, Cervical cancer, Infection, World Health Organization, Diagnosis, NMIBC, Comparison, Cervical weakness, Multimedia, Death, ASCO, Breast cancer, Eli Lilly, Tislelizumab, Prevalence, MIBC, Neoadjuvant therapy, HPV, Human papillomavirus infection, LSIL, New Drug Application, NMPA, National Health Commission, Central China, Kidney cancer, Women's health, National Cancer Center, PD-1, WHO, Mortality, HSIL, Conditional sentence, Internet, Weak topology, Patient, Senior, State Council, NDA, Incidence, Head, National Medical Products Administration, Miscarriage

This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.

Key Points: 
  • This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.
  • Asieris Pharmaceuticals will leverage both in-house discoveries and external partnerships to enrich its gynecological portfolio, thereby reinforcing its leadership in women's health.
  • In November 2020, the World Health Organization (WHO) released a Global Strategy to Accelerate the Elimination of Cervical Cancer.
  • To further deliver its strategic vision and commitment in the realm of women's health, Asieris Pharmaceuticals has announced the establishment of the Women's Health Business Unit.

Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Conference, Economics, Bladder cancer, Growth, Heart, Bank statement, Nadofaragene firadenovec, Schizophrenia, Investment, Webcast, Cardiovascular disease, KarXT, Fine chemical

This represents underlying growth of 11% year-over-year prior to Biohaven-related payments and reflects the strong performance of Royalty Pharma’s diversified royalty portfolio.

Key Points: 
  • This represents underlying growth of 11% year-over-year prior to Biohaven-related payments and reflects the strong performance of Royalty Pharma’s diversified royalty portfolio.
  • Royalty Pharma also expects Net cash provided by operating activities to be approximately $2,980 million to $2,990 million for full year 2023.
  • Royalty Pharma’s management will host a conference call to discuss Royalty Pharma’s fourth quarter and full year 2023 results in February 2024.
  • Royalty Pharma will present at the 42nd Annual J.P. Morgan Healthcare Conference at 12:00 p.m.